肠道菌群对异基因造血干细胞移植结果的影响  

Effects of intestinal microbiota on outcome of allogeneic hematopoietic stem cell transplantation

作　　者：葛静[1] 刘会兰[1] 

机构地区：[1]安徽医科大学附属省立医院血液内科,合肥230001

出　　处：《国际输血及血液学杂志》2017年第4期322-325,共4页International Journal of Blood Transfusion and Hematology

基　　金：安徽省科技厅2017年度重点研究及开发计划项目（1704a0802149）

摘　　要：肠道菌群在维持正常的肠上皮和肠道免疫功能中发挥重要作用。接受异基因造血干细胞移植（allo—HSCT）的患者在移植过程中，因化疗、全身照射（TBI）及抗菌药物的使用，改变机体原有肠道菌群的构成，导致共生菌减少、菌群多样性降低。肠道菌群与宿主免疫系统相联系，通过改变肠道免疫耐受及免疫应答功能，影响患者allo—HSCT后并发症的发生和移植相关死亡率（TRM）。抗菌药物的合理选用，以及益生菌、益生元的适当使用，可以减少allo—HSCT过程中对肠道菌群多样性的破坏，改善患者预后。笔者拟就患者接受allo—HSCT后，肠道菌群改变对其免疫功能及预后的影响进行综述。The intestinal microbiota play an important role in the maintaining of a normal-functioned intestinal epithelial and intestinal immune system. The pretransplant conditioning regimens including chemotherapy, total body irradiation （TBI） and the use of antibiotics during the procedure of allogeneic hematopoietic stem cell transplantation （allo-HSCT）, which have caused changes in the constitution of original intestinal microbiota, leading to a reduction in the number of symbiotic bacteria and the loss diversity of intestinal microbiota. By connecting with the immune system of host, intestinal microbiota can change immune tolerance and immune response of patients who received allo-HSCT, thus casting influence on the occurrence of complications and transplant-related mortality （TRM） of patients receving allo-HSCT. The correct selection of antibiotics, along with reasonable use of probioties and prebiotics will effectively reduce the damage to diversity of intestinal microbiota during allo-HSCT, as well as improve the prognosis of patients. Authors mainly discuss the role of intestinal microbiota variation on the immune system and prognosis of patients receving allo-HSCT.

关 键 词：造血干细胞移植 移植物抗宿主病 肠道菌群 

分 类 号：R457.7[医药卫生—治疗学]